A Stake in Health: Bláthnaid Bergin, Haleon PLC's Independent Director, Purchases Ordinary Shares in the Company

Further bolstering her stake in one of the world’s leading consumer health companies, Bláthnaid Bergin, Independent Non-Executive Director of Haleon PLC, has purchased additional shares in the company in a move that communicates her unwavering confidence in the firm’s future. The transaction, which was carried out on 16 May, 2025 on the London Stock Exchange, has been disclosed in keeping with UK Market Abuse Regulations that enforce the transparency of such transactions by Persons Discharging Managerial Responsibilities (PDMRs).

Bergin purchased 6,145 Haleon ordinary shares at a price of £4.0427 each. As a high-ranking executive at the company, Bergin’s investment is not just a financial commitment, but also an act of faith in the company’s continued success as a global leader in consumer health.

Such purchases by company insiders are typically interpreted as signals of the insiders’ belief in the firm’s prospects. The additional investment by a board member, particularly an independent non-executive director like Bláthnaid Bergin, who is not involved in the day-to-day operations suggests increased confidence in the company’s strategic trajectory. This transaction brings visibility to Haleon’s potential for growth and creates expectations of greater business stability and sustained financial health for the company moving forward.

As the company continues on its path of providing consumers with trusted health solutions, the investment by one of their own is a testament to Haleon’s unwavering commitment to improving everyday health. This incremental investment is indeed a vote of confidence, clearly stating that the company’s health is in a perfect state as reinforced by its stakeholders.